2006
DOI: 10.1016/j.lungcan.2006.01.002
|View full text |Cite
|
Sign up to set email alerts
|

Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2006
2006
2016
2016

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 42 publications
0
3
0
Order By: Relevance
“…In this regard, we should underline that all our patients, except one, were treated within 60 days after surgical procedure and 61% of them received chemotherapy as well. By the way, a study by Pinto et al [19] did not report any case of malignant seeding after sole chemotherapy in a series of 54 patients. This fact may suggest an effect of chemotherapy on the incidence of drain site seeding.…”
Section: Efficacy Of Radiotherapy In Preventing Procedures Tract Metasmentioning
confidence: 91%
“…In this regard, we should underline that all our patients, except one, were treated within 60 days after surgical procedure and 61% of them received chemotherapy as well. By the way, a study by Pinto et al [19] did not report any case of malignant seeding after sole chemotherapy in a series of 54 patients. This fact may suggest an effect of chemotherapy on the incidence of drain site seeding.…”
Section: Efficacy Of Radiotherapy In Preventing Procedures Tract Metasmentioning
confidence: 91%
“…Formal QOL was conducted in the study by Nowak et al 106 The authors reported that those patients who responded had greater improvement on the European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire-Cancer global QOL scale compared to those who did not respond (p ϭ 0.006); however, the effect did not persist past the completion of treatment. Pennucci et al, 92 Breau et al, 95 Ardizzoni et al, 96 Middleton et al, 101 Favaretto et al, 104 Pinto et al, 105 Byrne et al, 108 and Kasseyet et al 109 all observed improvements in symptoms in responding patients as well as in some patients with stable disease. High levels of hematologic toxicity were reported in most trials.…”
Section: Non-platinum-based Combination Chemotherapymentioning
confidence: 99%
“…The side effects of MTX are stomatitis and alimentary canal bleeding,6,7 while MIT causes hematological and hepatic adverse effects 8,9. To prolong the survival period, heighten the cure rate, and reduce the systemic toxicity of MTX/MIT in treating cancer patients, various combination regimens, such as MIT/MTX/mitomycin followed by cisplatin/gemcitabine for treating unresectable malignant pleural mesothelioma,10 MTX/MIT/mitomycin C for treating advanced breast cancer,1114 MIT/cyclophosphamide/MTX/5-flurouracil/prednisone for treating advanced breast cancer,15 MIT/MTX/folinic acid/methylprednisolone/vincristine/granulocyte for treating acute lymphoblastic leukemia,16 carmustine/doxorubicin/etoposide/vincristine/cyclophosphamide/MIT/cytarabine/MTX/citrovorum factor for treating non-Hodgkin lymphoma,17 and MIT/MTX/citrovorum for treating either metastatic or locally advanced transitional cell carcinoma of the bladder,18 have been used. Besides, MTX- and MIT-related combinations were used to reduce the toxicity of other anticancer drugs, such as MTX/MIT/mitomycin C combination being used to reduce nausea, vomiting, alopecia, and cardiotoxicity of doxorubicin-based protocols 19.…”
Section: Introductionmentioning
confidence: 99%